Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion

Bone Marrow Transplantation volume 43, pages 347–348 (2009)Cite this article

Sezary syndrome (SS) and mycosis fungoides are the most common forms of primary cutaneous T-cell lymphomas. SS is the leukemic variant of cutaneous T-cell lymphoma, characterized by CD4+ T cells, the Sezary cells, circulating in the peripheral blood, clonally expanded and identified by the rearrangement of T-cell receptor. The disease has an aggressive course with an average survival of 2–4 years.1

Allogeneic hematopoietic SCT (HSCT) provides a potentially curative approach for such patients, suggesting a role for graft-versus-tumor effect exerted by donor T cells.2 Because of toxicity and high risk of non-relapse mortality, patients heavily pretreated or of advanced age and/or with comorbidities are generally considered ineligible for a myeloablative allogeneic transplant. However, the use of conditioning regimens at reduced intensity (RIC) made allogeneic transplant feasible in these unfit patients.2

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Diamandidou E, Cohen PR, Kurzrock R . Mycosis fungoides and the Sezary syndrome. Blood 1996; 88: 2385–2409.

    CAS  PubMed  Google Scholar 

  2. Molina A, Zain J, Arber DA, Angelopolou M, O’Donnell M, Murata-Collins J et al. Durable clinical cytogenetic and molecular remission after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 2005; 25: 6163–6171.

    Article  Google Scholar 

  3. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al., for the ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713–1722.

    Article  CAS  PubMed  Google Scholar 

  4. Olavarria E, Child F, Woolford A, Whittaker SJ, Davis JG, McDonald C et al. T-cell depleted and autologous stem cell transplantation in the management of tumor stage mycosis fungoides with peripheral blood involvement. Brit J Haematol 2001; 114: 624–631.

    Article  CAS  Google Scholar 

  5. Burt RK, Guitart J, Traynor A, Link C, Rosen S, Pandolfino T et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft versus tumor effect. Bone Marrow Transplant 2000; 25: 111–113.

    Article  CAS  PubMed  Google Scholar 

  6. Duarte RF, Schmitz N, Servitje O, Sureda A, on the behalf of the Lymphoma Working Party of the EBMT. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant 2008; 41: 597–604.

    Article  CAS  PubMed  Google Scholar 

  7. Soligo D, Ibatici A, Berti E, Morandi P, Longhi E, Venegoni L et al. Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen. Bone Marrow Transplant 2003; 31: 663–666.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy

    L Cudillo, R Cerretti, G De Angelis, M Postorino, A Picardi, M Mirabile, M Cantonetti & W Arcese

  2. Dermatopatico Immacolata Institute, IRCCS, Rome, Italy

    G Baliva

  3. Blood Bank, Hematology, Tor Vergata University, Rome, Italy

    A Lanti

Authors
  1. L Cudillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Cerretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Baliva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G De Angelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Postorino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Picardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Mirabile
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Lanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Cantonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W Arcese
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Rome Transplant Network

Corresponding author

Correspondence to L Cudillo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cudillo, L., Cerretti, R., Baliva, G. et al. Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion. Bone Marrow Transplant 43, 347–348 (2009). https://doi.org/10.1038/bmt.2008.333

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.333

This article is cited by

Search

Advanced search

Quick links